Cisatracurium Besylate Injection 20mg/10ml Cisatra

Descriptions: Cisatracurium Besylate is used both before and during operation to relax muscles and make intubation easier. This drug should only be administered by your doctor or a person working closely with them.

High Alert Drugs: When this medication is administered incorrectly, there is a higher risk that it will seriously injure the patient. Ther.

A non-depolarizing, intermediate-acting neuromuscular blocking medication is cisatracurium besylate (NMBD). The structure of the 1R cis-1-prime R cis isomer of astacurium, cisatracurium, is benzylisoquinoline.

• Cisatracurium’s typical adverse effects could include:
• a slow heartbeat
• vertigo; or
• flushing (warmth, redness, or tingly feeling).

Guidelines for administering Cisatracurium injection (5 mg/ml) are shown in Table 6. In patients receiving long-term (up to 6 days) infusions of cisatracurium in the intensive care unit, the median time to complete spontaneous recovery was roughly 50 minutes.

Cisatracurium Besylate Inj can be administered as a sedative or adjuvant to general anesthesia in the intensive care unit (ICU) to relax skeletal muscles and facilitate tracheal intubation and mechanical breathing.

Three of the 21 patients who received 3xED95 cisatracurium showed hemodynamic changes greater than 20% (2 showed hypotension and 1 tachycardia), while two of the 21 patients who received high-dose cisatracurium showed a tachycardia that was predetermined to be statistically but not clinically significant.

Conclusions: According to the findings of this clinical investigation, cisatracurium is a good option for individuals with renal failure. The considerable variation in the recovery parameters in patients with renal failure is indicative of the requirement for intraoperative neuromuscular surveillance.

Existing research on muscle relaxants suggests that succinylcholine, a depolarizing neuromuscular blocker, is mostly responsible for MH; nevertheless, there have been a few isolated instances of MH being caused by nondepolarizing NM blockers. Cisatracurium-induced MH has only ever been documented once before.

In summary, this research proved that cisatracurium’s onset time was unaffected by storage at ambient temperature. It offers justification for keeping cisatracurium at room temperature for a maximum of 21 days.

Atracurium is a more potent neuromuscular blocking agent than cisatracurium at the same dose (2 ED95), while cisatracurium at higher doses (4 ED95 and 6 ED95) offers more potent, quicker neuromuscular blocking with longer duration of action, stable hemodynamic status, and no histamine-related side effects.

Check this Neurology Medicines product Cinnarizine 25mg STUGICO-25 or you may explore more Neurology Medicines products by Clicking here 

We are an exporter from India and work in excess countries like the UAE, Oman, Qatar, Myanmar, Saudi Arabia, Netherlands, Albania, Saint Lucia, Jordan, Romania, South Africa, etc.